Latest Breaking News On - Discovery engine - Page 14 : comparemela.com

Immunome Reports First Quarter 2023 Financial Results

Immunome, Inc. , a biopharmaceutical company that utilizes its human memory B cell platform to discover and develop first-in-class antibody therapeutics to improve patient care, today reported. | May 5, 2023

City ofUnited kingdomUnited statesAnthony tolcherPurnanand sarmaJohn lambertMatthew robinsonDrug administrationExchange commissionImmunome incDiscovery engineAntibody drug conjugateImmunome announced strategic collaborationDiscover multiple novel oncologyAnnounced formationAnnual world

Arvinas Reports First Quarter 2023 Financial Results and Provides Corporate Update

–Multiple vepdegestrant studies enrolling globally, including Phase 1, 2, and 3 studies– – Preliminary data from the Phase 1b combination trial of vepdegestrant + palbociclib. | May 5, 2023

United statesKirsten owensOerth bioTimothy shannonJohn houstonJeff boyleDrug administrationAmerican association for cancer researchDevelopment expensesPfizer incProgram leadershipFoundation annual huntington disease therapeutics conferenceArvinas incExchange commissionPredict your therapeutic responseImaging and

Arvinas to Present at the Bank of America Securities 2023

NEW HAVEN, Conn., May 03, 2023 (GLOBE NEWSWIRE) Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs.

United statesSean cassidyLas vegasKirsten owensJeff boyleArvinas incBusiness developmentChief financial officerRandy teelSenior vice presidentAmerica securitiesDiscovery engineNasdaq arvnRvinas incProstate cancerProtein degradation

Arvinas and Quantum Leap Healthcare Announce Clinical Study to Evaluate Vepdegestrant (ARV-471) in I-SPY-2 Endocrine Optimization Platform (EOP) Clinical Trial

Arvinas and Quantum Leap Healthcare Announce Clinical Study to Evaluate Vepdegestrant (ARV-471) in I-SPY-2 Endocrine Optimization Platform (EOP) Clinical Trial
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesSan franciscoJohn houstonLaura essermanPfizer incPrnewswire arvinas incExchange commissionDrug administrationUniversity of californiaQuantum leap healthcare collaborativeOptimization platformQuantum leapDiscovery engineLeap healthcare collaborativePredict your therapeutic responseImaging and

Arvinas to Present at Stifel Targeted Oncology Day

NEW HAVEN, Conn., April 21, 2023 Arvinas, Inc. , a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that Ian Taylor,. | April 21, 2023

Ian taylorJeff boyleSean cassidyArvinas incChief scientific officerChief financial officerStifel targeted oncology dayDiscovery engineNc stock exchangePress releaseAn arvn us04335a1051